GIT1 and breast cancer: When the data were stratified into breast cancers by different ER statuses, a more pronounced distinction between high and low GIT1 was observed in the ER(−) patients (Fig. 1i, j; n = 779, P = 0.0007, log-rank test, hazard ratio 0.68, 95% confidence interval (CI) 0.54–0.85) than in the ER(+) patients (Fig. 1h, j; n = 2527, P = 0.032, log-rank test, hazard ratio 0.85, 95% CI 0.74–0.99).